



Texas-Israel Healthcare & Life Sciences Innovation Conference

ISRAEL INNOVATION PARTNERSHIPS &
TEXAS AS THE "THIRD COAST"



In partnership with DLA Piper and The Paul E. Singer Foundation
In collaboration with Korenvaes Management
Held at UT Southwestern Medical Center on October 25th 2019



Conference Guide

Conference Context	5
Texas-Israel Alliance: The Mission	6
Proclamation by Governor Abbott	7
Opening Remarks	10
George Seay	10
Dr. Daniel Podolsky	11
The Case for Texas: Texas as the “Third Coast”	11
The Israeli Life Science Innovation Ecosystem Explained	19
“Advancing the Ecosystem & Capital Raising” Discussion	21
“UT Southwestern Medical Center Partnership with Rabin Medical Center”	26
FDA Principal Deputy Commissioner Amy Abernethy Fireside	30
“Impactful Big Data in Healthcare” Discussion	33
Israel-Texas Healthcare Collaboration & Case Studies	38

Sponsors

In partnership with:



In collaboration with:



Silver Sponsors:

Lyda Hill WorldLink



In partnership with



Conference Context

The Texas-Israel Alliance Healthcare & Life Sciences Innovation Conference is the flagship conference for Texas-Israel collaboration in life sciences and healthcare innovation.


Few technology areas are more core to the happiness and longevity of our society than healthcare. Advances in healthcare innovation not only expand economic horizons: they improve the quality of life of those afflicted with diseases, they extend the lifetimes of entire populations, and reduce the suffering of all people around the world by improving their quality of life.

Texas and Israel are at the forefront of many of the technological advances that fundamentally drive health, as well as long-term economic growth and prosperity for the communities in which these technologies are cultivated.

Texas is poised to become the “Third Coast” for healthcare innovation in the US, with its rich network of institutions, companies, and investors. Enter Israel, one of the world’s leading innovators in healthcare for pharmaceuticals, digital health technologies, and medical devices.

Through strategic partnerships, the Texas and Israeli healthcare ecosystems fit together like two pieces of the same puzzle.

Ground-breaking innovations have been made in Texas and Israel for decades now. The Texas-Israel Alliance Healthcare Innovation Initiative is designed to create and develop projects and models to bring cooperation between the Lone Star States to the next level.



Texas-Israel Alliance: The Mission

The Texas-Israel Alliance is a non-profit with a mission of economic diplomacy, elevating business leaders in key industries to forge economic and strategic relationships that strengthen the United States as well as the US-Israel economic relationship. In this, Texas is perfectly poised to lead.

Texas is the nation's second largest economy, the fastest growing, most diverse, and the best environment for business in the nation.

Israel is a world technology leader in the very areas where Texas requires innovative solutions, and Texas has deep expertise within areas of emerging business in Israel.

The Texas-Israel Alliance serves as a centralized hub, around which leadership in industry, government, and academic institutions can pool together interests and resources toward partnerships with Israel, allowing us to create something greater than the sum of its parts.

Chairman of the Texas-Israel Alliance, George Seay

CEO of the Texas-Israel Alliance, Toba Hellerstein

For more information, please write Toba Hellerstein at: Toba.Hellerstein@texasisrael.org





GOVERNOR GREG ABBOTT

Greetings:

As Governor of Texas, I am pleased to welcome everyone to the Texas-Israel Alliance Healthcare Innovation Conference at the UT Southwestern Medical Center.

Of all our nation's many allies, Israel is among the closest. Not only is Israel a crucial trading partner, it also stands firmly with our nations ideals of freedom.

The motivation of this conference is to elevate the life sciences technologies, boost the Texas economy, and promote greater Texas-Israel cooperation. Health care institutions, companies, and Texas investors will come together to exchange knowledge and work in unison to improve industry initiatives in pharmaceuticals, digital health technologies, and medical device equipment.

This conference will be a wonderful opportunity for you all to make new contacts and benefit from a cultural exchange. I commend you all on your efforts to continue building the bridge between Texas and Israel.

I extend a special welcome to our visitors. Dallas has something for everyone, from thrilling professional sports, world-class shopping, and exquisite art. I encourage you all to learn, explore, and enjoy.

First Lady Cecilia Abbott joins me in wishing you a successful conference.

Sincerely,

A handwritten signature in black ink that reads "Greg Abbott".

Greg Abbott
Governor



DLA PIPER, CONFERENCE PARTNER

DLA Piper is a global law firm with lawyers located in more than 40 countries throughout the Americas, Europe, the Middle East, Africa and Asia Pacific, positioning us to help clients with their legal needs around the world.

Clients range from multinational, Global 1000, and Fortune 500 enterprises to emerging companies developing industry-leading technologies. They include more than half of the Fortune 250 and nearly half of the FTSE 350 or their subsidiaries. We also advise governments and public sector bodies.

Life Sciences Practice

As the legal matters confronting our life science clients are varied, so are the skill sets we employ. DLA Piper's life sciences team comprises lawyers with legal, scientific and medical knowledge who understand the complexity of the business and regulatory environments in which our clients operate. We have over 300 dedicated life sciences lawyers.

The challenges facing today's biotechnology and medical device companies are greater than ever. For companies to take promising therapies from the laboratory to the market, they must protect those therapies from IP, regulatory and reputational risks.

Furthermore, the last few years have seen increasing pressure from many sides: demand for greater shareholder return, loss of key revenue streams due to patent expiration or generic challenges, fierce competition in key therapeutic areas, pricing pressures from health care payors, increased government regulation beyond core safety issues, rising costs of R&D, challenges in maximizing return in emerging markets and aggressive government enforcement action.

Our life sciences sector team is one of the largest and most active of any law firm. Operating as one team across more than 30 jurisdictions, we combine subject matter experience with considerable knowledge of the sector, including the scientific, medical, regulatory, commercial and enforcement environments facing our biopharmaceutical, medical device, research and diagnostics clients.

DLA Piper's team includes award-winning lawyers practicing litigation, compliance and investigations, IP strategy and enforcement, M&A, licensing and distribution and clinical trial advice.

- More than half of the World's 50 Most Innovative Companies are DLA Piper clients (Fast Company 2019)
 - Ranked #1 in M&A activity worldwide for the past nine years (Mergermarket)
 - In the last 3 years alone, over 2,000 venture capital financings totaling more than US\$27 billion
 - In the past 5 years, nearly 300 US public offerings (equity and debt), including over 25 IPOs, raising more than US\$58 billion
 - Only firm in the top five in each of M&A, private equity, and venture capital (Pitchbook)
 - "Best of the Best" in Providing Value for the Dollar (BTI 2018)
-



START-UP NATION CENTRAL, SUPPORTED BY THE PAUL E. SINGER FOUNDATION, CONFERENCE PARTNER

Start-Up Nation Central is an independent non-profit that builds bridges to Israeli innovation.

We connect business, government, and NGO leaders from around the world to Israeli innovation, through highly customized business engagements, and through Start-Up Nation Finder – an easy to use, up-to-date, free online platform for discovering and connecting with thousands of relevant innovators.

We identify technological sectors with high-growth potential, and help them develop to maturity. We currently focus on the Digital Health, AgriFoodtech and Industry 4.0 sectors, exposing them to global audiences, helping them develop practical tools, attracting investors, and establishing and nurturing tech communities to increase collaboration, knowledge-sharing, and skill expansion.

We accumulate knowledge and generate in-depth insights about Israel's innovation sector, and share these findings with our clients and partners. Start-Up Nation Central – your partner for Israeli innovation.



UT SOUTHWESTERN MEDICAL CENTER, HOST

UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education.

Founded in 1943, UT Southwestern Medical Center has had four Nobel Prizes awarded to its faculty since 1985. In the 2010-2011 edition of U.S. News & World Report's Americas Best Hospitals, UT Southwestern is nationally ranked in six specialty-care areas: urology, diabetes/endocrinology, gynecology, kidney disorders, neurology and neurosurgery, and ear, nose and throat. The medical center is also among the nation's best performers in biology and biochemistry research in achieving clinical breakthroughs.

The faculty of more than 2,500 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in about 70 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 3 million outpatient visits a year.

Opening Remarks

George Seay

CHAIRMAN OF THE TEXAS-ISRAEL ALLIANCE & OF ANNANDALE CAPITAL



George Seay is a nationally recognized speaker, civic leader, and financial industry CEO with senior level experience working in government and on GOP political campaigns. George is the founder and chairman of Annandale Capital, a global investment firm that manages capital for clients all across the country. He is the Chairman of the Texas-Israel Alliance.

Mr. Seay has significant public policy experience through his work for the Governor of Texas and the Deputy Secretary of State at the U.S. State Department in Washington.

Mr. Seay serves on numerous boards including Chairman of the Clements Center for National Security at the University of Texas and the Texas-Israel Chamber of Commerce. He is the former Chairman of Associated Republicans of Texas.

Mr. Seay received his B.A. summa cum laude and his MBA with a Dean's Award for Academic Excellence from the University of Texas. He graduated Cum Laude from the Southern Methodist University School of Law, where he served as President of the SMU Law Review Association.

Dr. Daniel Podolsky

PRESIDENT OF UT SOUTHWESTERN MEDICAL CENTER



Dr. Daniel K. Podolsky became the third President of UT Southwestern Medical Center on September 1, 2008. As President, he holds the Philip O'Bryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration. He is a Professor of Internal Medicine and holds the Doris and Bryan Wildenthal Distinguished Chair in Medical Science.

Since arriving at UT Southwestern, Dr. Podolsky's agenda has focused on keeping UT Southwestern at the frontiers of science by enhancing its faculty and activities in basic, translational, and clinical research and on promoting clinical transformation through a commitment to excellence & innovation in patient care.

His priorities also include ensuring that UT Southwestern educates and trains future physicians, scientists, and allied health care professionals in programs that optimally prepare them for the changing landscape in scientific research and health care delivery, and he has launched important new initiatives in global health and faculty diversity.

Prior to becoming the President of UT Southwestern, Dr. Podolsky was the Mallinckrodt Professor of Medicine at Harvard Medical School, the Chief of Gastroenterology at Massachusetts General Hospital, and the Chief Academic Officer of Partners HealthCare System in Boston. Dr. Podolsky received his undergraduate degree from Harvard College, summa cum laude, and his medical degree from Harvard Medical School, followed by residency training in Internal Medicine and a fellowship in Gastroenterology at Massachusetts General Hospital.

The Case for Texas: Texas as the “Third Coast”

Moderated by George Seay

PANELISTS

- Julie Goonewardene, Chief Innovation & HR Officer at University of Texas System
- Tom Luce, Founder and Chairman of Texas 2036
- Dr. Vincent Michaud, Deputy Chief Health and Medical Officer at NASA
- Colonel Ortiz, Chief Medical Modernization Division, Army Futures Command
- Wayne Roberts, CEO of Cancer Prevention and Research Institute of Texas (CPRIT)

Julie Goonewardene

SR. ADVISOR TO THE CHANCELLOR, CHIEF TALENT AND INNOVATION OFFICER



Julie Goonewardene has enjoyed a distinguished career as an entrepreneur, CEO, investor and board member. Best known for her expertise in converting the promise of innovation into reality and results, she currently serves as Senior Advisor to the Chancellor of The University of Texas System, and Chief Talent and Innovation Officer. Within this role, Julie leads a venture fund for the University and leverages her extensive experience to advance key university initiatives that support UT institutions and the greater Texas community.

With a passion for creating cultures that inspire and positively challenge those around her, Julie has started, led and negotiated successful exits for technology companies, and her contributions at various research institutes helped transform nascent discoveries into products, partnerships and companies, often with life-changing outcomes.

Julie’s board experiences include the American Medical Association, the U.S. Department of Commerce’s National Advisory Council on Innovation and Entrepreneurship (NACIE), and the American Association for the Advancement of Science (AAAS) Committee on Science, Engineering and Public Policy. She currently serves as chairperson of Diaceutics, a healthcare diagnostic technology company she helped take from private to public in 2018.



THE UNIVERSITY of TEXAS SYSTEM
FOURTEEN INSTITUTIONS. UNLIMITED POSSIBILITIES.

The University of Texas System

The University of Texas System is one of the nation's largest systems of higher education, with 14 institutions that educate nearly 240,000 students. Each year, UT institutions award more than one-third of all undergraduate degrees in Texas and almost two-thirds of all health professional degrees. With about 21,000 faculty – including Nobel laureates – and more than 83,000 health care professionals, researchers, student advisors and support staff, the UT System is one of the largest employers in the state.

Life-changing research and invention of new technologies at UT institutions places the UT System among the top 10 "World's Most Innovative Universities," according to Reuters. The UT System ranks fifth in the nation in patent applications, and because of the high caliber of scientific research conducted at UT institutions, the UT System is ranked No. 1 in Texas and No. 2 in the nation in federal research expenditures.

In addition, the UT System is home to three of the nation's National Cancer Institute Cancer Centers – UT MD Anderson, UT Southwestern and UT Health Science Center-San Antonio – which must meet rigorous criteria for world-class programs in cancer research. And the UT System is the only System in the country to have four Clinical and Translational Science Awards (CTSA) from the National Institutes of Health.

UT was the only system of higher education in the nation that established not one, but two new medical schools in 2016. These schools are at The University of Texas at Austin and UT Rio Grande Valley.

Tom Luce

FOUNDER OF TEXAS 2036



Tom Luce's life has been one of family, professional accomplishments, public service and social entrepreneurship.

Tom was the founding and managing partner of the Hughes and Luce law firm. He was lead attorney on multibillion mergers and litigation and was selected at various points in his career as one of the best attorneys in Dallas, Texas and the United States.

His public service in Texas was distinguished by gubernatorial & legislative appointments to major state positions including Chief Justice of the Supreme Court pro tempore, Sunset Commission, Cancer Prevention & Research Institute, Texas Commission on Judiciary & Chief of Staff, Select Committee on Public Education.

On the national level, he was appointed as Assistant Secretary of Education by President George W. Bush, confirmed by the United States Senate and appointed to The Library of Congress Board by the Speaker of the U.S. House of Representatives.

In addition to Texas 2036, Tom has founded and lead numerous other nonprofit organizations dedicated to serving the needs of others including the Texas Business and Education Coalition, Just for the Kids, Data Quality Campaign, the National Center for Educational Accountability, the National Math and Science Initiative and the Meadows Mental Health Policy Institute.

He has authored two books on improving public education and has taught at the Kennedy School of Government at Harvard, the University of Texas LBJ School of Public Affairs, Southern Methodist University and the University of Texas at Dallas. He received his undergraduate and law degrees from Southern Methodist University.



Texas 2036

Texas 2036 uses data, research, and leading expertise to enable Texans to make informed decisions to ensure Texas continues to be the best place to live and do business through its bicentennial in 2036 and beyond.

Informed by decades of public policy experience at the local, state, and national level, in 2016, Tom Luce founded Texas 2036 amid growing concern that without careful consideration, planning, and

decision-making regarding the future, the tremendous opportunities Texas offers may not exist for future generations.

Texas 2036 believes it's important that Texans from all viewpoints and perspectives engage in a thoughtful discussion about the future of our state. Therefore, we share articles, stories, and information from a broad range of sources including those that may or may not represent the eventual views or policy positions of Texas 2036.

Dr. Vincent Michaud


NASA'S DEPUTY CHIEF HEALTH AND MEDICAL OFFICER



Dr. Vincent Michaud serves as NASA's Deputy Chief Health and Medical Officer. He is responsible for the oversight of all health and medical activities at NASA, including medical aspects of all national and international NASA missions involving humans.

He holds an M.D. degree from the University of Texas Southwestern Medical School in Dallas, and completed residencies in Aerospace Medicine and Occupational Medicine at the USAF School of Aerospace Medicine at Brooks AFB, Texas. A Fellow of the Aerospace Medical Association, he is certified by the American Board of Preventive Medicine (Aerospace and Occupational Medicine). He has extensive experience in the clinical practice of aerospace medicine and occupational medicine as well as in administrative medical management.

Dr. Michaud retired from the United States Air Force in 2012 after serving for 26 years. His military decorations include the Legion of Merit Medal and the Chairman of the Joint Chiefs of Staff Excellence in Medicine Award. Dr. Michaud is also designated an FAA Aviation Medical Examiner.



National Aeronautics and Space Administration (NASA)

National Aeronautics and Space Administration (NASA), independent U.S. governmental agency established in 1958 for the research and development of vehicles and activities for the exploration of space within and outside the Earth's atmosphere.



The Office of the Chief Health and Medical Officer (OCHMO) was created to undertake responsibility for the health of the NASA workforce in areas such as policy, medical guidelines, best medical practices, professional development and training, and medical quality assurance. Specifically, the office is responsible for policy and oversight for occupational health, aerospace medicine, medicine in extreme environments, protection of research subjects and patients, quality assurance, public health issues, and professional health education and development.

As NASA continues its mission to carry human presence deeper into space and expand our knowledge of the universe, the Agency's efforts also reach into another territory—the inner space of the human body. NASA partnerships are exploring the use of carbon nanotubes to diagnose and treat brain tumors, perfecting fiber optic probes for detecting cataracts that cloud vision, and developing software for recognizing and managing depression. From experiments on the International Space Station to aeronautics research, NASA programs are also resulting in spinoffs that improve fitness, treat disease, and save lives. These resulting medical technologies are among the more than 1,700 NASA spinoffs recorded since 1976.



Col. Rick Ortiz

CHIEF OF MEDICAL MODERNIZATION AT US ARMY FUTURES COMMAND



Colonel Ortiz's currently serves as Chief, Medical Modernization Division, Army Futures Command. His most recent assignment was as Commander, United States Army Medical Activity, Fort Sill, Oklahoma. Previously, he served in the Pentagon as Deputy Joint Staff Surgeon, Office of the Joint Staff Surgeon, the Joint Staff. Prior to the Joint Staff, he served as Executive Officer to the G-3/5/7, OTSG and Army Medical Command and as Medical Evacuation Staff Officer, Office of the Surgeon General, Falls Church, Virginia.

Colonel Ortiz was commissioned a 2nd Lieutenant in the Medical Service Corps following graduation from Embry-Riddle Aeronautical University (ERAU) in April 1992 with a Bachelor's Degree in Aeronautical Science. He is a distinguished graduate from the Army War College with a Master's Degree in Strategic Studies. He also holds a Master's of Science Degree specialized in Aviation Safety and Management from ERAU. He is a graduate of the Combined Arms and Services Staff School and Command and Staff General College.

COL Ortiz's awards and decorations include the Defense Superior Service Medal, Legion of Merit, Meritorious Service Medal, Air Medal, Joint Commendation Medal, Army Commendation Medal; Armed Forces Expeditionary Medal; Humanitarian Service Medal; Kosovo Campaign Medal; United Nations Medal; NATO Medal; Army Achievement Medal. He is authorized the Army Staff and Joint Staff badge.



US Army Futures Command

Army Futures Command leads a continuous transformation of Army modernization in order to provide future warfighters with the concepts, capabilities and organizational structures they need to dominate a future battlefield.

The establishment of Army Futures Command marks one of the most significant Army reorganization efforts since 1973, when the U.S. Army disestablished the Continental Army Command and Combat Development Command, and redistributed their functions between two new commands, U.S. Army Forces Command and U.S. Army Training & Doctrine Command.

Strategic We must create and deliver focused, prioritized concepts, organizational designs and capabilities to achieve Defense Planning Guidance objectives and meet Army Senior Leader guidance to address mid and long-term challenges.

Effective We must deliver what warfighters need, when they need it, in a timely and affordable manner.

Innovative We must create and cultivate a culture that front-loads smart risks through iteration and prototyping.

Agile We must be willing to fail early and responsibly and learn from our failures and successes. We must be creative and not become victim to a "that is not how we do it here" mentality.

Unified We must become "one team" with a laser focus on creating speed through shared goals and understanding, disciplined initiative, enabled decision making at the lowest possible level & delivering valued outcomes for the Army.

Wayne Roberts

CEO OF THE CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS (CPRIT)



Wayne Roberts has been with the Cancer Prevention and Research Institute of Texas since December 2012, first as Interim Executive Director and then as Chief Executive Officer.

Prior to four years with The University of Texas Health Science Center at Houston as Associate Vice President for Public Policy, Wayne's career emphasized public finance and budget, especially related to higher education and economic development. He held numerous senior positions under Governor Rick Perry.

Wayne served Governor George W. Bush as Deputy and Acting State Budget Director and was Lt. Governor Bob Bullock's special assistant for budget and human services following 18 years with the Legislative Budget Board.

Wayne was named the 2018 Administrator of the Year by the Texas State Agency Business Administrators' Association. He has also been awarded life membership in the National Association of State Budget Officers after holding several positions, including president, on their executive committee. In 2009 Governor Perry appointed Wayne to the State Pension Review Board for a term that ended in 2016.

He received a B.A. with honors and special honors in government from The University of Texas at Austin and a Masters from the Lyndon B. Johnson School of Public Affairs at UT.



Cancer Prevention and Research Institute of Texas (CPRIT)

Texas voters overwhelmingly approved a constitutional amendment in 2007 establishing the Cancer Prevention and Research Institute of Texas (CPRIT) and authorizing the state to issue \$3

billion in bonds to fund groundbreaking cancer research and prevention programs and services in Texas.

CPRIT's goal is to expedite innovation in cancer research and product development, and to enhance access to evidence-based prevention programs throughout the state. Under the guidance of its governing body, the Oversight Committee, CPRIT accepts applications and awards grants for a wide variety of cancer-related research and for the delivery of cancer prevention programs and services by public and private entities located in Texas.

All CPRIT-funded research is conducted in state by Texas-based scientists and reflect CPRIT's mission to attract & expand the state research capabilities & create high quality new jobs in Texas.

The Israeli Life Science Innovation Ecosystem Explained

Guy Hilton

GENERAL MANAGER OF START-UP NATION CENTRAL



With more than 15 years of marketing and management experience, Guy Hilton leads strategy, research, partnerships and engagements, product, and marketing at Start-Up Nation Central and is in charge of the organization's day-to-day operations. Previously, Hilton was Start-Up Nation Central's Chief Marketing Officer, responsible for both Marketing and Business Development.

Prior to joining Start-Up Nation Central, Mr. Hilton served as the Head of Marketing for Amdocs Portfolio, where he helped leading service providers devise their marketing and pricing strategies to better differentiate themselves in the market. Mr. Hilton transformed Amdocs' marketing organization, bringing it into the digital marketing era. Earlier in his career, he worked at Kodak and Microsoft, winning awards for marketing excellence.

Start-Up Nation Central

Start-Up Nation Central is an independent non-profit that builds bridges to Israeli innovation.

We connect business, government, and NGO leaders from around the world to Israeli innovation, through highly customized business engagements, and through Start-Up Nation Finder – an easy to use, up-to-date, free online platform for discovering and connecting with thousands of relevant innovators.

We identify technological sectors with high-growth potential, and help them develop to maturity. We currently focus on the Digital Health, AgriFoodtech and Industry 4.0 sectors, exposing them to global audiences, helping them develop practical tools, attracting investors, and establishing and nurturing tech communities to increase collaboration, knowledge-sharing, and skill expansion.

We accumulate knowledge and generate in-depth insights about Israel's innovation sector, and share these findings with our clients and partners. Start-Up Nation Central – your partner for Israeli innovation.

Claire Aldridge

ASSOCIATE VICE PRESIDENT FOR COMMERCIALIZATION AND BUSINESS DEVELOPMENT AT UT SOUTHWESTERN MEDICAL CENTER



Claire Aldridge, Ph.D. serves as Associate Vice President for Commercialization and Business Development at UT Southwestern Medical Center. She recently rejoined UT Southwestern after eight years with Reditex Ventures, a local biotech venture fund. Dr. Aldridge brings more than 20 years' experience facilitating the translation of scientific discoveries into patient and commercial benefits.

Dr. Aldridge has leveraged her training as a translator, or liaison, between scientists and non-scientists, communicating effectively about the potential of science. Her roles have included technology commercialization; improving patient outcomes through quality based initiatives; working with disease-specific nonprofits; development and venture philanthropy; biotech and life science investing through venture capital.

In addition to broadening the pipeline of commercialization opportunities for UT Southwestern discoveries, she plans to bring her science communication, commercialization and venture capital skills together with other science and civic leaders to grow and more deeply establish a biotech ecosystem in the North Texas region.

Dr. Aldridge received her Ph.D. from Duke University in the Department of Immunology and Program in Genetics, and her Bachelor of Science in Biomedical Science is from Texas A&M University.

“Advancing the Ecosystem & Capital Raising” Discussion

Moderated by: John Gilluly III

Panelists

- Doug French, Managing Director at Sante Ventures
- RA Session, Chief Business Officer at BridgeBio
- Nicole Small, CEO Lyda Hill Philanthropies and LH Capital
- Lou Tartaglia, Venture Partner at 5AM Ventures
- Peter Urbanowicz, Principal at Paintbrush Partner

John Gilluly III

PARTNER AND GLOBAL CO-CHAIR, CORPORATE AT DLA PIPER



John Gilluly represents clients across a range of industries and focuses on capital markets transactions, SEC reporting and compliance, mergers and acquisitions, private equity and venture capital transactions, and corporate governance matters.

John is the Global Co-Chair of DLA Piper's Corporate Group. John is also a member of DLA Piper's Global Board and its Executive Committee.

Recent Experience

Outside corporate and securities counsel to multiple public companies

Counsel to numerous issuers, venture capital firms and private equity firms in preferred stock and levered transactions

Representation of:

- Upstream producer on the sale of oil and gas assets to a Special Purpose Acquisition Company (SPAC)
- Private equity-backed national restaurant company in its US\$780 million acquisition by a public buyer
- Private equity firm in the US\$2.4 billion sale of upstream oil and gas assets
- National restaurant company in the acquisition of its largest franchisee
- Private equity platform company in its US\$500 million international add-on acquisition
- Public software company in its US\$4.5 billion take-private transaction

- SaaS HCM company in its initial public offering and follow-on offerings
- SaaS FinTech company in its initial public offering and follow-on offerings
- Underwriters in follow-on offering of a leading payments company
- Private equity firm in its leveraged acquisition of multiple employee benefit firms
- Venture-backed software company in its acquisition by private equity firm



Doug French

MANAGING DIRECTOR OF SANTE VENTURES

Douglas D. French has over 30 years of experience as a distinguished healthcare executive. He is a co-founder and managing director of Santé Ventures with \$600M under management through three early-stage healthcare venture funds.

He is the past President and Chief Executive Officer of Ascension Health based in St. Louis, Missouri. Ascension Health is the largest nonprofit system in the United States with over 100 facilities operating in 36 markets and 20 states with operating revenue of over \$21 billion.

French completed his undergraduate degree at Trevecca University in Nashville, Tennessee and his graduate degree at Xavier University in Cincinnati, Ohio. He serves on numerous boards of directors including Herman Miller, Inc (MLHR), Powered Health, The Nashville Health Care Council, The Legacy Senior Communities Dallas, the BDS Committee and the P&A Committee, Jewish Federation of Dallas, and 6 privately-held companies representing \$270 mill. of invested capital.

French is a Fellow in the American College of Healthcare Executives and has published and spoken extensively on leadership development, healthcare ventures, healthcare collaboration and reform.



Founded in 2006, Santé Ventures is a specialized healthcare and life sciences investment firm with over a half-billion dollars in capital under management. The Firm invests in early-stage companies developing innovative new medical technologies, biotechnologies and digitally-enabled healthcare services. Since inception, the Firm has made over 30 portfolio investments, including Claret Medical (Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), Molecular Templates (MTEM), AbVitro (Celgene) and Explorys (IBM Corp). Santé invests nationally and is headquartered in Austin, Texas, with additional offices in Houston. For more information, please visit www.santeventures.com.

RA Session II

CHIEF BUSINESS OFFICER AT BRIDGEBIO



R.A. Session II is currently Chief Business Officer of the gene therapy subsidiaries of BridgeBio.

Previously, he was Senior Vice President of Corporate Strategy and Business Development at AveXis from until it's \$8.7B acquisition by Novartis. Prior to AveXis, Mr. Session served in various roles for PTC Therapeutics, Inc., most recently as the vice president of commercial development. He previously served in various roles at Reata Pharmaceuticals, Inc., most recently as the senior director of strategic planning and finance. Prior to Reata Pharmaceuticals, Mr. Session worked at AstraZeneca Pharmaceuticals as senior manager of commercial portfolio and post deal analytics in the managed markets group. He began his career in the pharmaceutical division of Johnson & Johnson, serving as senior financial analyst in the strategic business group. \RA serves on the board of directors for Lung Therapeutics, ReCode Therapeutics, and Sandhill Therapeutics.

Mr. Session is a member of the Kauffman Fellows Society. Mr. Session received a B.S.B.A. in finance from the University of North Carolina at Charlotte, a M.S.F. in finance from Texas A&M University-Commerce and an M.B.A. from Texas A&M University-Commerce.



BridgeBio

BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases.

Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance to conduct early-stage development means that for many, treatments have not been forthcoming. We are committed to bridging this gap: between business case and scientific possibility, between patient and hope. BridgeBio creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible.

BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity.

Nicole Small

CEO AT LH CAPITAL



Trustee Nicole G. Small brings a unique background in nonprofit and foundation leadership and business experience to CFT. She serves as the president of the Lyda Hill Foundation and CEO of LH Holdings, Inc., where she oversees all aspects of investments and philanthropic endeavors. LH Holdings, Inc., and the Lyda Hill Foundation are related entities which use their resources to fund game-changing advances in science and nature, empower nonprofits and improve the local communities of greatest importance to the organizations' founder, Miss Lyda Hill.

Nicole is well-known for her leadership and passion for STEM education, previously serving as CEO of the Perot Museum of Nature and Science.

Her STEM-focused experience dovetails perfectly with CFT's education funding and related programs to strengthen the preparation of more students for success in life.

As CEO of the Perot Museum of Nature and Science from 2002-2014, Nicole directed all aspects of day-to-day operations and the development of the new downtown facility that has garnered international attention.

Nicole holds a B.A. from the University of Pennsylvania and an MBA from Northwestern's Kellogg School of Management. She has worked at McKinsey & Co., Goldman Sachs and multiple technology and venture capital firms.

Lyda Hill Holdings

Lyda Hill reflects a mix of entrepreneurial vigor and a commitment to balancing profit with purpose. Miss Hill is committed to investing in catalytic, solution-oriented initiatives that have the potential to impact global issues such as food security and safety, water conservation, urban green spaces, medical research, public health and other related efforts.

Miss Hill proactively looks for opportunities where her funding can lead to meaningful change. Projects that are the best fit often involved:

- Tackling problems that are bold, complex and what some might call "impossible"

- Supporting extraordinary leaders with the passion and determination to build scalable solutions
 - Funding elements that other funders can't or won't support
 - Inspiring others to invest or de-risking an opportunity for others to follow
 - Engaging in thoughtful and strategic collaboration
-

Lou Tartaglia

VENTURE PARTNER AT 5AM VENTURES



Dr. Lou Tartaglia, PhD joined 5AM Ventures in 2016 and has served as both Head of 5AM's internal de novo new company formation initiative, and more recently as a Venture Partner. He is also a founding member of Lone Star Bioventures. Dr. Tartaglia has over 25 years of scientific and therapeutic product project leadership in the biotech industry. Dr. Tartaglia previously served as a Partner at Third Rock Ventures where he played an integral role in the overall scientific diligence, formation and development of its portfolio companies. He also served as Chief Executive Officer of Solstice Biologics and General Manager at GeneLogic. He was formerly the Vice President of Metabolic Diseases at Millennium Pharmaceuticals where he was responsible for the discovery and development of multiple therapeutic programs. Dr. Tartaglia completed his postdoctoral work at Genentech in the laboratory of Dr. David Goeddel. He received his PhD in Biochemistry at the University of California, Berkeley in the laboratory of Dr. Bruce Ames and his BS in Chemistry at the State University of New York at Albany.

Peter Urbanowicz

PRINCIPAL AT PAINTBRUSH PARTNER



Mr. Urbanowicz most recently served as Chief of Staff of the U.S. Department of Health and Human Services for Secretary Alex M. Azar II. Mr. Urbanowicz was appointed to his position by the President in January 2018. As HHS Chief of Staff, Mr. Urbanowicz was responsible for coordinating the efforts of all of HHS' operating agencies and staff divisions.

Peter Urbanowicz is currently a principal with Paintbrush Partners in Dallas, Texas. As a corporate officer, board member, Presidential appointee, restructuring consultant and attorney he has built and led highly functioning management teams and improved the financial performance and operations of leading health organizations.

Prior to his service as HHS Chief of Staff, Mr. Urbanowicz was a Managing Director with Alvarez & Marsal, a global business consulting firm, where he focused on performance improvement, financial turnaround and management advisory services. Mr. Urbanowicz led A&M's healthcare regulatory and compliance practice.

Earlier in his career, Mr. Urbanowicz served as Executive Vice President, General Counsel and Secretary of Tenet Healthcare Corporation (NYSE: THC). Prior to his service as HHS Deputy General Counsel, Mr. Urbanowicz was a partner in the law firm of Locke, Liddell & Sapp LLP.

Mr. Urbanowicz received his B.A. and J.D. degrees from Tulane University.

"UT Southwestern Medical Center Partnership with Rabin Medical Center"

Presented by: Dr. David Russell & Dr. Boaz Tadmor

Dr. David Russell, Ph.D

VICE PROVOST AND DEAN OF RESEARCH AT UT SOUTHWESTERN MEDICAL CENTER



Dr. David Russell is the Vice Provost and Dean of Research Professor and the Eugene McDermott Distinguished Chair in Molecular Genetics.

David W. Russell received a BA degree in biology from UT Austin in 1975 and a PhD in chemistry from the University of North Carolina in 1980. He was a Damon Runyon Cancer Research Foundation postdoctoral fellow from 1980-1982 with Nobel laureate Dr. Michael Smith (Chemistry, 1993) at the University of British Columbia. He joined the faculty at UT Southwestern in 1982, was promoted to professor in 1990, and received the McDermott Distinguished Chair of Molecular Genetics in 1992.

Dr. Russell's research interests are in lipid metabolism, in particular the enzymatic pathways that dispose of cholesterol. His laboratory has isolated over a dozen genes that encode enzymes involved in cholesterol breakdown, and has identified the molecular bases of six human genetic diseases characterized by abnormal cholesterol and lipid metabolism.

Dr. Russell and Dr. Joseph Sambrook are the authors of the best selling molecular biology cloning manual, *Molecular Cloning*, published by Cold Spring Harbor Laboratory Press.

Dr. Russell is the recipient of a Research Career Development Award from the National Institutes of Health, the Katz Award from the American Heart Association, the Kilby Science Place Award

from Texas Instruments, the Oppenheimer Award from the Endocrine Society, the Windaus Prize from the Falck Foundation, the Avanti Award in Lipids from the American Society for Biochemistry and Molecular Biology, the Barbara Bowman Distinguished Geneticist Award from the Texas Genetics Society. He was elected to the National Academy of Sciences in 2006 and the American Academy of Arts & Sciences in 2011.

Dr Boaz Tadmor

DIRECTOR OF R&D AT RABIN MEDICAL CENTER



Dr. Tadmor was born in Israel and graduated Hadassah Medical School in 1982. His fellowships were in Internal Medicine and Clinical Immunology. Dr. Tadmor served 23 years in the Israeli army-Medical corps. His final position was Physician in Chief-Home Land Security.

Dr. Tadmor is an expert in Emergency and Disaster Leadership and Management.

2003-2004: Columbia University NYC, and visiting scientist in Emergency and Disaster Management consulting NIH, and DARPA.

2005-2015: Tel-Aviv University : Teaching Leadership and Disaster Management for Masters degree.

2007-2015: CEO Beilinson Hospital, Tertiary, Academic, Level 1 Trauma center.

2015-2019: Heading "Rabin Medical Center" Research Authority. Main areas of research: complexity, complex adaptive systems.



Rabin Medical Center

Rabin Medical Center (RMC), at the forefront of Israel's healthcare system, was established in 1996 in memory of the late Prime Minister Yitzhak Rabin by combining two existing hospitals: Beilinson and Hasharon.

Rabin medical center has about 4,500 employees and an operating budget of nearly \$600M. With over 1,000,000 Annual Patient Visits, 165,000 Emergency Room Admissions, 32,000 Surgical

Procedures, 8,000 Births, 4,500 RMC's Outstanding Staff Members, 1,050 Patient Beds 50 Research Laboratories, 37 Operating Rooms, Tertiary hospital, Academic Medical Center, and Level 1 trauma Medical Center, RMC strives to offer state-of-the-art medicine, combining the use of advanced equipment and technologies with humane and compassionate care.

A prestigious teaching hospital affiliated with the Tel Aviv University Sackler School of Medicine, RMC has been distinguished since its founding for setting new standards of medical care and for pioneering breakthroughs in technology and medical expertise, while maintaining the highest principles of excellence and compassion toward patients and their families. A center of excellence in a wide range of medical sub-specialties, RMC's Organ Transplantation Department is the number one transplantation facility in the country, performing some 65% of Israel's organ transplants annually.

The department of Cardiothoracic Surgery, by far the largest of its kind in Israel, performs over 1,200 heart and lung operations annually. RMC's Davidoff Center is a national focus of excellence in cancer care, treating some 20% of all oncology patients in the country. Women's Hospital and Raphael Recanati Genetic Center provide comprehensive care in their fields, and the Cardiothoracic Surgery and Cardiology Departments are the largest in the country.

Rabin Medical Center has Israel's only dedicated transplant facilities capable of performing kidney, lung, heart and liver transplants. Rabin Medical Center's Cardiothoracic Surgery Department and its Oncology Institute are the largest in the country, and its heliport and Level 1 Trauma Center provide vital emergency services throughout the region. RMC is a major tertiary referral center for patients from all over Israel and beyond.

Rabin Medical Center Partnership with UT Southwestern Medical Center LED BY DAVID WIESSMAN, FOUNDER OF THE TEXAS-ISRAEL ALLIANCE

David Wiessman, prominent business leader and philanthropist, and founder of the Texas-Israel Alliance (formerly Texas-Israel Chamber of Commerce), created a pivotal partnership between Rabin Medical Center and UT Southwestern in 2010 in an innovative affiliation program, initially for \$2 million in partnership dollars.

As a part of the agreement, the two internationally recognized institutions collaborated on faculty and student exchange programs, as well as the



development of joint studies, research and training activities, and other educational programs of mutual interest.

The joint agreement outlines collaboration between UT Southwestern and Rabin on:

- Joint research conferences and symposia;
- Reciprocal exchange of students, post-graduate trainees or faculty in the areas of medicine, nursing, collaborative research projects, exchange of publications, reports or other academic information;
- Exchange of cooperation regarding the organization, delivery and management of health care services;
- Professional development.

This is the first agreement between UT Southwestern and Rabin Medical Center, and it is extensive in that it covers aspects ranging from joint development of intellectual property, joint publication of research and special assistance for participating students, researchers and faculty in securing required visas, work permits and housing in both countries.

Established a global partnership to foster a faculty exchange program and joint research projects. Each institution brings unique strengths to the collaboration, leveraging the expertise of leading specialists at UT Southwestern and RMC to address complex medical problems and provide exceptional patient care. Past projects have enabled knowledge-sharing and joint research in areas such as oncology and emergency medicine.

In 2018, David Wiessman made a lead gift of \$350,000 to expand the collaboration in three areas: heart disease, inflammatory bowel disease, and fatty liver disease.

The collaboration partnership will hold events in Dallas in November 2019, and in Tel Aviv in 2020 in order to raise additional funds. A mutual scientific board was created for the partnership, and a call for mutual researches was published. The board will finalize the chosen research for the final decision of each institution's CEO.

FDA Principal Deputy Commissioner Amy Abernethy Fireside

Presented by: Amy Abernethy

Moderated by: Danny Tobey

Amy Abernethy

PRINCIPAL DEPUTY COMMISSIONER OF FOOD AND DRUGS (FDA)



As the Principal Deputy Commissioner of Food and Drugs, Amy P. Abernethy, M.D., Ph.D., helps oversee the agency's day-to-day functioning and directs special and high-priority initiatives that cut across offices overseeing FDA's regulation of drugs, medical devices, tobacco and food. As acting Chief Information Officer, she oversees FDA's data and technical vision, and its execution.

Dr. Abernethy, a hematologist/oncologist and palliative medicine physician, is an internationally recognized clinical data expert and clinical researcher. Her areas of expertise include cancer data, real world evidence, clinical trials, health services research, patient reported outcomes (PROs), clinical informatics, and patient-centered care.

Before coming to FDA, Dr. Abernethy served as chief medical officer, chief scientific officer, and senior vice president for oncology at Flatiron Health (a member of the Roche Group), where she led the research oncology, clinical operations and data science teams, and contributed to the overall strategic vision of the company, including directing their research vision on real world evidence.

Prior to that, Dr. Abernethy was a professor of medicine at Duke University School of Medicine, where she ran the Center for Learning Health Care in the Duke Clinical Research Institute and the Duke Cancer Care Research Program in the Duke Cancer Institute. At Duke, she pioneered the development of technology platforms to spur novel advancements in the care of people with cancer and other serious life-limiting illnesses.

Dr. Abernethy was formerly an appointed member of the National Academy of Medicine's National Cancer Policy Forum, an elected member of the American Society for Clinical Investigation, and Past President of the American Academy of Hospice & Palliative Medicine.

Dr. Abernethy received her M.D. at Duke University, where she also did her internal medicine residency, served as chief resident, and completed her hematology/oncology fellowship. She

received her Ph.D. from Flinders University in Australia, with a focus on evidence-based medicine and clinical informatics, and her bachelor's degree from the University of Pennsylvania.



Food and Drug Administration (FDA)

The Food and Drug Administration is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation.


FDA also has responsibility for regulating the manufacturing, marketing, and distribution of tobacco products to protect the public health and to reduce tobacco use by minors.

FDA is responsible for advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health.

FDA also plays a significant role in the Nation's counterterrorism capability. FDA fulfills this responsibility by ensuring the security of the food supply and by fostering the development of medical products to respond to deliberate and naturally emerging public health threats.

Danny Tobey

PARTNER AT DLA PIPER AND BOARD MEMBER OF THE TEXAS-ISRAEL ALLIANCE



Danny Tobey is a medical doctor and software entrepreneur who represents life sciences, technology and healthcare clients in all manner of disputes, from tort and contract claims to regulatory and patent cases. Danny also leads the firm's team that focuses on efforts to assist companies as they navigate the legal landscape of emerging and disruptive technologies, while helping them understand the legal and compliance risks arising from the creation and deployment of AI systems. In 2019, he received a Burton Award from the Library of Congress recognizing "the best of the best writers in the legal profession" among the top 1,000 largest US law firms.

A graduate of Harvard College, Yale Law School, and UT Southwestern Medical School, Danny has litigated successfully some of his clients' most challenging and important cases. He designed the

winning scientific case in the first Hatch-Waxman suit in the Eastern District of Texas. He obtained a unanimous reversal in federal appellate court in an R&D tax case of first impression, leading to a highly-cited published opinion and increasing his clients' tax refund from low-six to high-seven figures. He has successfully handled as lead counsel litigations arising from M&A transactions for a molecular diagnostics company and others. He has represented healthcare and hospital clients in matters ranging from credentialing and internal investigation to peer review and business tort claims.

Danny has been a thought leader on emerging legal issues in medicine and AI. His writing has appeared in the National Law Journal, the 2018 Proceedings of the Association for the Advancement of Artificial Intelligence, Yale Journal of Law & Technology and Health Law Litigation. He has consulted with companies ranging from startups to Fortune 100 on legal issues in the creation and adoption of AI. He serves on the Continuously Learning Systems task force with leading industry representatives. His original medical research is published in Pediatric Blood & Cancer and the Journal of Child and Adolescent Psychopharmacology.

Danny serves on the executive committees of the Yale Law School Association, the Parkland Foundation supporting the Parkland Health and Hospital System and the AT&T Performing Arts Center. He serves on the boards of directors of the Perot Museum of Nature and Science, the SPCA of Texas and the regional Anti-Defamation League. He has co-chaired the Judiciary and Membership & Admissions Committees of the Dallas Bar Association and sits on the governing council of its Business Litigation Section.

Doug Deason

PRESIDENT OF DEASON CAPITAL SERVICES AND BOARD MEMBER OF THE TEXAS-ISRAEL ALLIANCE



Doug is the President of Deason Capital Services, LLC, the Deason family office, as well as the President of The Deason Family Foundation. DCS manages family assets including a substantial holding of Xerox Corporation and Conduent Inc. shares, controlling interest in Dallas Capital Bank, municipal bonds, holdings in the global tax services firm Ryan, LLC as well as holdings in Foreland Resources, LLC, an oil and gas operating company. DCS also manages investments in hotels, PE funds, debt funds, oil and gas funds and LPs, subprime auto loans, real estate, mezzanine loans and other assets and investments.

Prior to joining the family office, Doug was CEO of Precept Builders, Inc., a Deason family owned nationwide commercial builder, and co-managing partner of Evergreen Realty Partners, a commercial and multifamily development company based in Dallas.

Doug currently serves on the Board of Directors of Ryan, LLC, Foreland Resources, Deason Capital Services, Dallas Capital Bank, Intrexon Energy Partners, and DCS Hospitality. He also serves on the Advisory Board of Valesco Industries, a Dallas based private equity and debt fund, the Texas Public Policy Foundation, the Lone Star Justice

Alliance, the Executive Board of The Bobby Lyle School of Engineering at Southern Methodist University and is Chairman of the Advisory Board of The Darwin Deason Institute for Cyber Security at SMU. Doug has served on numerous boards of private and public companies as well as several charitable organizations and private schools.

He has served as the Vice Chairman of Finance of the Dallas County Republican Party for several years and he served on the Executive Committee of, and was Membership Chair for, the West Texas Chapter of the Young Presidents Organization. Doug graduated from the University of Arkansas in 1984 with a degree in Data Processing/Quantitative Analysis.

“Impactful Big Data in Healthcare” Discussion

Moderated by: Max Korenvaes

Panelists

- Randy Peak, Partner at DLA Piper
- Mathew Thomas Pulickel, Senior Vice President of Emerging Technologies at WorldLink
- Aman Quadri, Chief Strategy Officer at AMSYS & CEO at AMCHART Initiative
- Bharathwaj Rajagopal, General Manager of Microsoft US Healthcare Services
- Dr. Boaz Tadmor, Director of R&D at Rabin Medical Center in Israel

Max Korenvaes, Principal and Managing Partner at Korenvaes Management
SPONSOR



Max currently leads the biotech, medical device, technology, and agribiotech strategies at Korenvaes Management where he is a Principal and Managing

Partner. Korenvaes Management is a “multi-strategy” family office that invests in all areas of the capital structure in the private and public markets. Max served on the board of Xhale Assurance, Inc. prior to its acquisition and currently serves on the boards of Double Helix Management, Inc., POP/FEMSelect Inc., and Stride LLC. Mr. Korenvaes is an Entrepreneur in Residence at UT Southwestern Medical Center.

Max Korenvaes covered biotech, medical device, etc. companies as an analyst-intern at Highside Capital Management and financial services and healthcare services as an analyst at Hersh Family Investments before becoming a Finance Director at Cardworks Servicing. Shortly thereafter, Max founded Apollo Laboratories, a chemistry and hematology clinical laboratory and Double Helix Management, a pathology practice management and development company with clients that service over three hundred physicians in Texas and surrounding states with his partners.



Korenvaes Management

Korenvaes Management is a family office located in Dallas, Texas. Korenvaes comes from a legacy of investing in public securities in the equity, credit, and hybrid securities markets, but has reoriented its strategic direction to focus on direct, private equity and venture capital investing in the healthcare services, biotech, medical devices, agribiotech, and the technology and healthcare spaces. Korenvaes has built healthcare delivery platforms from scratch and has cultivated relationships with a broad, multidisciplinary network of physicians in Texas by consistently delivering in-network healthcare infrastructure. We view the collection of assets within these strategies as leverageable toward creating “orthogonal” solutions in the healthcare space. Deriving more efficiency in the “clinical trial domain” is a priority focus of the Korenvaes office.

Randy Peak, Partner at DLA Piper

SPONSOR



Randy Peak, former General Counsel for an internationally recognized health system and academic medical center and prior Deputy General Counsel for a leading healthcare supply chain and data analytics company, focuses on healthcare and life sciences transactions and regulatory

counseling in areas including digital health and healthcare technology; telehealth services; data privacy and security; hospital operations and physician practices; health and wellness services; clinical laboratories and pathology practices; clinical research, trials and studies; healthcare supply chain, pharmaceutical and medical device manufacturing; blockchain and emerging technologies; retail pharmacies and pharmacy benefit management services; behavioral health and treatment facilities; veterinary operations; and healthcare acquisitions, ventures and related transactions.

Randy has more than two decades of experience providing strategic legal counsel to healthcare and technology innovators and industry leaders in their efforts to operationalize and commercialize innovative and emerging technologies and structure and negotiate complex transactions.

Leveraging his extensive experience and knowledge of in-house legal operations, Randy also provides general counsel services to his legal and business clients that includes functioning as outside general counsel, advisory board formation and representation, and legal department operations counseling and advice.

Mathew Thomas Pulickel

SENIOR VICE PRESIDENT OF EMERGING TECHNOLOGIES AT WORLDLINK

Sponsor



Mathew Pulickel is driving WorldLink's Emerging Technology Consulting Practice. He has over 20 years of experience in strategic consulting focused on delivering services to improve and transform performance, while lowering costs. Mathew has a degree in Corporate Finance and a minor in Accounting. He brings a fresh perspective to WorldLink as he helps clients understand how technology enables their business or even plays a disruptive role. Mathew is an avid member on the boards of Need

Him and Shiloh Restored, and when he's not working, Mathew is a family man. He loves spending time with his wife and two boys engaging in activities such as watching movies or volunteering.

//ORLD LINK

WorldLink

WorldLink is a global technology firm that delivers three distinct areas of Solutions: Talent, Consulting, and Managed.

WorldLink's core is built on "Inspired Intellect." We provide unmatched experience in our Talent, Cloud, and Data/Analytics Leaders. In addition, our focus on strategy and vision leads to strong relationships with our diverse Client base. WorldLink fulfills the unique Client vision instead of offering standard "out-of-the-box" Solutions.

At WorldLink, success is always a shared journey.

We are technology driven solution providers, competing with the world's best and across the globe to ensure that our projects and services are globally benchmarked. Our technological initiatives ideate and implement solutions across functions, for sustainable and profitable growth of the company.

Aman Quadri

CHIEF STRATEGY OFFICER AT AMSYS & CEO AT AMCHART INITIATIVE



Aman Quadri, PT, DPT, Cert. MDT, began his career in hardware technology in the 90's eventually selling his small company and moving into healthcare where he earned his Master's and then eventually his Doctor of Physical Therapy. Once in practice, he realized the many issues surrounding antiquated health care technology, decreased patient engagement, and lack of data to make informed decisions that led to starting Transwise, a back office healthcare IT and services company in 2010.

Since then, he has worked as a healthcare consultant, home health practitioner, and worked to help create efficiencies in the health space. In 2017, he joined AMSYS Blockchain as the CEO and was tasked to lead a healthcare project named AMCHART, a suite of technology projects designed to aggregate health data and also to help practitioners bridge the divide between patient and provider interactions. After 18 months, that "project" morphed into a revenue generating company. In Aman's view, every patient should have 24/7 access to his records, understand what that data means, and be able to share it through permissioned access, while every physician should be able to capture to most insight from the data they receive.

Bharathwaj Rajagopal

GENERAL MANAGER OF MICROSOFT US HEALTHCARE SERVICES



Bharat has worked for Microsoft for 18 years. Currently, he is the General Manager of the US Healthcare Services Operating Unit.

As the leader of US Healthcare Services, Bharat works with a passionate team of Sales and Delivery professionals focused on leveraging the power of the Microsoft Cloud to make Digital Transformation real for the US Healthcare industry. His organization sells and delivers solutions across our Consulting, Digital and Support businesses for the leading 400+ Providers, Payors, Life Sciences and Health Software and Supply Chain customers in the US.

Bharat holds an MBA from Northwestern University, a Masters in Mechanical Engineering from Toledo University, and a Bachelor of Engineering from Malviya National Institute of Technology, Jaipur.



Microsoft

The Microsoft US Healthcare Services Operating Unit strives to achieve better outcomes across healthcare by improving patient experiences, orchestrating integrated operations across clinical and administrative staff, and gathering new levels of insight to improve operational outcomes.

Microsoft also helps clients deliver better care more securely, providing the right information at the right time for patients and staff, by putting people at the center and helping ensure the compliance, confidentiality, integrity, and accessibility of your data.

In addition, Microsoft helps enable personalized care by providing them with more control over their health. Microsoft empowers care teams, build more effective teams by providing deep insights from centralized data.

Microsoft streamlines and improve operations using clinical and business data. For providers, to meet increased patient expectations and improve satisfaction. For payers, to decrease member readmission rates and the risk of in-clinic infection. For Pharma and life sciences, to address rising drug development costs and manage cybersecurity threats.

The Microsoft Services implementations for bots, IoT, analytics and other solution offerings are ideal for customers such as healthcare providers, pharmaceutical companies, telemedicine providers, and health insurers that would like to embed AI in their systems. Microsoft offerings empower their patients, nurses, doctors, and other representatives to interact with medical information systems, while allowing the customer to improve processes, services, outcomes, and reduce costs.

Dr. Boaz Tadmor, Director of R&D at Rabin Medical Center (Bio see page. 26)

Israel-Texas Healthcare Collaboration & Case Studies

Moderated by: Anat Zeidman

Panelists

- Ori Hofnung, CEO of GiantLeap
- Lance Black, Associate Director of the Texas Medical Center Accelerator (TMCx)

Anat Zeidman

STRATEGIC PARTNER OF START-UP NATION CENTRAL



Anat Zeidman is a Texas based Strategic Partner with Startup Nation Central, a non-profit that connects businesses, NGOs and government leaders throughout the world with the people and technologies of Israel that can help them solve their most pressing challenges. In addition to her professional career, Mrs. Zeidman volunteers on the Surgical Innovation Task Force Committee at Houston Methodist. Mrs. Zeidman has over a decade of experience working within the Texas Medical Center and its member institutions, including serving as the Director of Healthcare and Business Development for AECOM, a Lead Program Manager for Memorial Hermann Hospital System, and a Facilities Planning and Development Project Manager at Texas Children's Hospital. Mrs. Zeidman, a native Israeli, received her B.S. in Architectural Studies from the University of Texas.

Ori Hofnung

CEO OF GIANTLEAP



Ori Hofnung is Co-Founder & CEO of GiantLeap, a science-backed gamified learning development assessment and decision support tool for children, driven by AI. GiantLeap provides parents and educators with the knowledge and guidance of child learning development experts at their fingertips by democratizing assessments of cognitive and behavioral abilities such as math, attention, memory,

spatial, motor, self-efficacy and social behavior; without professional supervision to produce a personalized work-plan designed to guide parents and educators in fostering the child's aptitudes and prioritize when and how to work on areas of difficulty.

Native of Israel, Ori spent most of his professional career overseas in the United States and Brazil where he held several executive positions in digital media ventures, with an emphasize on games and entertainment content products. His previous roles include Director of Global Client Relations at Tomodo and General Manager of Playbuzz Latin America.

Lance Black

ASSOCIATE DIRECTOR OF TEXAS MEDICAL CENTER ACCELERATOR TMCX



Lance Black, MD, MBID is the Associate Director of the Texas Medical Center's TMCx Accelerator program.

Dr. Black served previously as Medical Device Innovation Lead, and draws on his extensive military, medical, and engineering expertise to support the resident companies of TMCx in developing innovative healthcare technologies.

After earning his B.S. in Biological Engineering from Louisiana State University and his M.D. from LSU Health Sciences Center of New Orleans, Dr. Black served in the U.S. Air Force and deployed overseas twice: first as Chief of Medical Staff for Manas Transit Base in Kyrgyzstan, and then as a Squadron Flight Surgeon in Okinawa, Japan.

During his time in the armed forces, Dr. Black helped to create modular medical facilities for civilian use, and designed and implemented safety protocols for F-22 stealth fighter pilots and their crews.

Inspired from his work with Wounded Warrior amputees, Dr. Black utilized his background in Biological Engineering to focus on the design and development of medical devices. Following his exit from service, Dr. Black received his Masters of Biomedical Innovation & Development from Georgia Tech, including a year in their Masters of Industrial Design program.



Texas Medical Center

Located in the TMC Innovation Institute, the program provides startup companies with shared workspace, a curriculum tailored to the needs of health care entrepreneurs and the guidance of

over 200 [advisors](#) from the front lines of the industry. Companies have access to the world's largest medical center, all without membership fees or equity sharing.

Participants further develop their [companies](#) by attending a variety of workshops and hands-on events to gain insights from experts in every facet of running a health-related business: clinical trials, FDA regulations, HIPAA/HITECH compliance, hospital procurement, commercial pilots, intellectual property, licensing, fundraising, marketing and other critical areas.

In addition, participants work with the [TMCx team](#) to refine strategies and build relationships across the Texas Medical Center. Companies network with key thought leaders and mentors during the Advisor Pitch Event, the TMC Expert Forum and other scheduled sessions. The four-month program culminates with TMCx Demo Day, an exclusive presentation to hundreds of investors, corporate partners, hospital stakeholders, media and other guests.